The FDA granted approval to trastuzumab-anns (Kanjinti, Amgen/Allergan) biosimilar for all approved indications of the reference product, Herceptin (Genentech): the treatment (as adjuvant) of HER2-overexpressing metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Source link